In summary, our data indicated that ST3GAL5 could be a potential prognostic biomarker for clinical outcomes and might be a potential indicator of CD8+ T cell exhaustion in ccRCC patients. The gene discussed is CD8A; the disease is nonpapillary renal cell carcinoma.